Abstract

Regulatory T cells (Tregs) are critical mediators of immune homeostasis. The co-stimulatory molecule CD27 is a marker of highly suppressive Tregs, although the role of the CD27-CD70 receptor-ligand interaction in Tregs is not clear. Here we show that after prolonged in vitro stimulation, a significant proportion of human Tregs gain stable CD70 expression while losing CD27. The expression of CD70 in expanded Tregs is associated with a profound loss of regulatory function and an unusual ability to provide CD70-directed co-stimulation to TCR-activated conventional T cells. Genetic deletion of CD70 or its blockade prevents Tregs from delivering this co-stimulatory signal, thus maintaining their regulatory activity. High resolution targeted single-cell RNA sequencing of human peripheral blood confirms the presence of CD27CD70+ Treg cells. These findings have important implications for Treg-based clinical studies where cells are expanded over extended periods in order to achieve sufficient treatment doses.

Regulatory T cells maintain immune homeostasis and help control development of autoimmunity and allergy. Arroyo-Hornero et al show that upon prolonged stimulation, regulatory T cells may switch to an immunostimulatory phenotype by upregulating the expression of the co-stimulatory molecule CD70.

Details

Title
CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells
Author
Arroyo, Hornero Rebeca 1   VIAFID ORCID Logo  ; Georgiadis Christos 2 ; Peng, Hua 3   VIAFID ORCID Logo  ; Trzupek Dominik 4 ; Li-Zhen, He 5 ; Qasim Waseem 2 ; Todd, John A 4   VIAFID ORCID Logo  ; Ferreira, Ricardo C 4 ; Wood, Kathryn J 1 ; Issa Fadi 1   VIAFID ORCID Logo  ; Hester, Joanna 1   VIAFID ORCID Logo 

 University of Oxford, Transplantation Research and Immunology Group, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 UCL Great Ormond Street Institute of Child Health, Molecular and Cellular Immunology Unit, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201) 
 John Radcliffe Hospital, MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, Oxford, UK (GRID:grid.8348.7) (ISNI:0000 0001 2306 7492) 
 University of Oxford, JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
 Celldex Therapeutics, Inc., Hampton, USA (GRID:grid.417695.8) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2423651108
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.